ZL-2401 (Omadacycline) received funding support from National “Significant New Drugs Development Project”
Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, announced today that its innovative antibiotic ZL-2401 (Omadacycline) has been granted funding support from the National Major Scientific and Technological Special Project for Significant New Drugs Development in China. The grant will support the clinical research and new drug applications of ZL-2401.
The Significant New Drugs Development Project, which was launched in 2008, aims to encourage pharmaceutical companies and research institutions to develop medicines in 10 major disease areas that seriously endanger the health of Chinese people, including drug-resistant pathogen infections, in order to improve the nation’s drug innovation system. In 2016, 14 government agencies including the National Health Commission unveiled “the National Action Plan to Contain Antimicrobial Resistance (2016-2020)”. The plan clearly states its support for R&D of new anti-infection drugs, especially innovative therapies with different mechanisms of action and molecular structures.
This is the second project of Zai Lab supported by the Significant New Drugs Development Project following the study of “ZL-2306 (Niraparib) for the treatment of platinum-sensitive recurrent ovarian cancer,” acknowledging Zai Lab’s innovation capabilities and product values.
“We are very pleased that ZL-2401 can be supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development.” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab, “There are limited treatment options against drug-resistant bacteria in China with significant unmet medical needs. ZL-2401 will have the opportunity to improve the situation. We will strive to foster the development of ZL-2401 and other pipeline products to deliver our commitment to patients in China and around the world.”
About ZL-2401 (Omadacycline)
ZL-2401 is the first antibiotic in the class of aminomethylcyclines jointly developed by Zai Lab and Paratek. ZL-2401 can effectively overcome the common resistance mechanism of tetracyclines. Studies have shown that it has strong activity against methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococci (VRE). In October 2018, ZL-2401 was granted priority review and approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin/ skin structure infections (ABSSSIs) by FDA.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Our experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs worldwide. Our vision is to become a fully integrated innovative biopharmaceutical company, discovering, developing, manufacturing and commercializing products of our own and our partners, to promote the health and well-being of people all over the world.